P. Morel

发表

p53 Mutations Are Associated With Resistance to Chemotherapy and Short Survival in Hematologic Malignancies

B. Quesnel, E. Wattel, C. Preudhomme, 1994 .

A revised international prognostic score system for Waldenström’s macroglobulinemia

M. Dimopoulos, A. Duhamel, P. Morel, 2019, Leukemia.

Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment.

G. Salles, B. Coiffier, O. Casasnovas, 2001, The hematology journal : the official journal of the European Haematology Association.

Non-Hodgkin's lymphoma and Sjögren's syndrome. An immunopathological study of 113 patients.

P. Morel, F. Bauters, A. Janin, 1992, Clinical and experimental rheumatology.

The Clinical Spectrum of IgM-Related Amyloidosis: A French Nationwide Retrospective Study of 72 Patients

M. Bernard, B. Grosbois, C. Elie, 2008, Medicine.

Frequency of structural abnormalities of the long arm of chromosome 12 in myelofibrosis with myeloid metaplasia.

P. Morel, F. Bauters, J. Andrieux, 2002, Cancer genetics and cytogenetics.

A Randomized Prospective Study of Cefepime Plus Metronidazole with Imipenem-Cilastatin in the Treatment of Intra-abdominal Infections

P. Morel, J. Garbino, P. Villiger, 2007, Infection.

Prognostic significance of survivin expression in diffuse large B-cell lymphomas.

J Diebold, T. Molina, P. Gaulard, 2000, Blood.

Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia.

O. Casasnovas, S. Leprêtre, S. Chevret, 2021, Blood advances.

Impact of MICA and NKG2D polymorphisms in HLA-fully matched related and unrelated hematopoietic stem cell transplantation

P. Morel, L. Garçon, M. Diouf, 2018, Bone Marrow Transplantation.

Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.

A. Duhamel, E. Wattel, C. Preudhomme, 1993, Leukemia.

Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy

P. Morel, P. Fenaux, F. Bauters, 1991, British journal of haematology.

Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia.

E. Kimby, M. Dimopoulos, R. Kyle, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Increased trisomy 12 frequency and a biased IgVH 3-21 gene usage characterize small lymphocytic lymphoma.

C. Bastard, P. Morel, P. Duthilleul, 2010, Leukemia research.

Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab.

I. Dervite, P. Morel, D. Hober, 2001, The New England journal of medicine.

A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone

B. Pégourié, A. Vekhoff, S. Chevret, 2017, Leukemia & lymphoma.

Waldenström’s macroglobulinemia: prognostic factors and recent therapeutic advances

P. Morel, V. Leblond, O. Tournilhac, 2004, Clinical and Experimental Medicine.

First‐line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study

P. Feugier, S. Leprêtre, M. Béné, 2017, Hematological oncology.

Prognostic factors in myelodysplastic syndromes: critical analysis of the impact of age and gender and failure to identify a very‐low‐risk group using standard mortality ratio techniques

C. Declercq, P. Morel, P. Fenaux, 1996, British journal of haematology.

Prognostic value of the International Scoring System and response in patients with advanced Waldenström macroglobulinemia

A. Vekhoff, J. Tamburini, P. Morel, 2011, Haematologica.

Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).

A. Stamatoullas, P. Morel, P. Fenaux, 2010, Leukemia research.

10 Years Follow-up of the GELA LNH98.5 Study, First Randomized Study Comparing R-CHOP to CHOP Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma.

G. Salles, B. Coiffier, R. Bouabdallah, 2009 .

The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease.

F. Berger, É. Lepage, P. Morel, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients.

P. Gaulard, B. Coiffier, H. Tilly, 2003, Blood.

Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia.

E. Kimby, P. Morel, S. Treon, 2008, Blood.

Long-term outcome of follicular low-grade lymphoma a report of 91 patients

C. Declercq, P. Morel, F. Bauters, 1993, Annals of Hematology.

Feasibility of autologous bone marrow transplantation for early consolidation of follicular non‐Hodgkin's lymphoma

P. Morel, P. Fenaux, F. Bauters, 1991, European journal of haematology.

The VIM3-AraC regimen followed by autologous stem cell transplantation in refractory or relapsing aggressive non-Hodgkin's lymphoma. A prospective study of 71 consecutive cases

P. Morel, P. Fenaux, F. Bauters, 1999, Leukemia.

Role of early splenectomy in malignant lymphomas with prominent splenic involvement (primary lymphomas of the spleen). A study of 59 cases

P. Morel, P. Fenaux, F. Bauters, 1993, Cancer.

Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs.

P. Gaulard, B. Coiffier, H. Tilly, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study

B. Quesnel, C. Gisselbrecht, N. Brousse, 2000, Bone Marrow Transplantation.

Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte.

H. Tilly, N. Brousse, C. Sebban, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

T. Lister, B. Barlogie, M. Dhodapkar, 2003, Seminars in oncology.

Risk stratification in Waldenström macroglobulinemia

P. Morel, G. Merlini, 2012, Expert review of hematology.

Th17 and CD24hiCD27+ regulatory B lymphocytes are biomarkers of response to biologics in rheumatoid arthritis

P. Morel, P. Fardellone, J. Marolleau, 2017, Arthritis Research & Therapy.

The IL6(-174G/C) polymorphism is a prognostic factor for survival after treatment initiation in Waldenström macroglobulinemia patients aged 65 years or less

I. Dervite, P. Morel, X. Leleu, 2008, Haematologica.

Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system.

P. Morel, F. Bauters, J. Laï, 1996, Blood.

Cytogenetics of myelodysplastic syndromes.

P. Morel, P. Fenaux, J. Lai, 1996, Seminars in hematology.

High-dose therapy followed by stem cell transplantation in partial response after first-line induction therapy for aggressive non-Hodgkin's lymphoma.

P. Gaulard, B. Coiffier, H. Tilly, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia.

E. Kimby, M. Dimopoulos, D. Maloney, 2006, Clinical lymphoma & myeloma.

High-dose therapy and autologous stem cell transplantation in relapsing cutaneous lymphoma

C. Gisselbrecht, C. Lebbé, L. Dubertret, 2004, Bone Marrow Transplantation.

Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).

M. Dimopoulos, P. Sonneveld, P. Morel, 2013, Blood.

Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop

E. Kimby, N. Munshi, R. Kyle, 2013, British journal of haematology.

Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia

B. Quesnel, E. Bertrand, C. Preudhomme, 2013, American journal of hematology.

Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III)

P. Hari, O. Decaux, P. Morel, 2014, Haematologica.

Prognostic Factors and Long Term Outcome of 138 Adults with Systemic Anaplastic Large-Cell Lymphoma: a Retrospective Study by the Groupe d'Etude Des Lymphomes De l'Adulte (GELA)

P. Gaulard, B. Coiffier, H. Tilly, 2010 .

de novo myelodysplastic syndromes in adults aged 50 or less. A report on 37 cases.

C. Preudhomme, P. Morel, P. Fenaux, 1990, Leukemia research.

Appelbaum FR, Rowe JM, Radich J, Dick JE. Acute Myeloid Leukemia. Hematology Am Soc Hematol Educ Program. 2001:62-86. PMID: 11722979

E. Campo, P. Greenberg, J. Bennett, 2008 .

Low incidence of specific anti‐platelet antibodies detected by the MAIPA assay in the serum of thrombocytopenic MDS patients and lack of correlation between platelet autoantibodies, platelet lifespan and response to danazol therapy

E. Wattel, P. Morel, P. Fenaux, 1996, British journal of haematology.

Azacytidine in refractory or relapsed AML after intensive chemotherapy (IC): results of the French ATU Program

A. Stamatoullas, B. Quesnel, E. Wattel, 2010 .

Long-term survivors in myelodysplastic syndromes: a report on 63 cases and comparison with short and intermediate survivors.

E. Wattel, B. Hecquet, P. Morel, 1993, Leukemia research.

Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study.

K. Hoang-Xuan, O. Chinot, N. Martin-Duverneuil, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Whole Brain Radiotherapy (WBRT) Versus Intensive Chemotherapy with Haematopoietic Stem Cell Rescue (IC + HCR) for Primary Central Nervous System Lymphoma (PCNSL) in Young Patients: An Intergroup Anocef-Goelams Randomized Phase II Trial (PRECIS)

K. Hoang-Xuan, O. Chinot, P. Morel, 2016 .

Azacytidine (AZA) as First Line Therapy in AML: Results of the French ATU Program.

H. Dombret, A. Stamatoullas, B. Quesnel, 2009 .

A multivariate analysis of the survival of patients with aggressive lymphoma: variations in the predictive value of prognostic factors during the course of the disease. Groupe d'Etudes des Lymphomes de l'Adulte.

B. Coiffier, H. Tilly, C. Gisselbrecht, 1998, Cancer.

Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis.

C. Preudhomme, P. Morel, P. Fenaux, 1992, Leukemia.

Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation--results of a retrospective analysis on 120 patients autografted in a single institution.

M. Labopin, P. Morel, P. Fenaux, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

diagnosed acute promyelocytic leukemia: a pilot study on 26 cases complete remission rate and may prolong remissions in newly All-transretinoic acid followed by intensive chemotherapy gives a high

H. Dombret, H. Tilly, P. Morel, 2011 .

Splenic irradiation for chronic autoimmune thrombocytopenic purpura in patients with contra‐indications to splenectomy

P. Morel, P. Fenaux, F. Bauters, 1995, British journal of haematology.

Syndromes International Scoring System for Evaluating Prognosis in Myelodysplastic

G. Mufti, P. Greenberg, J. Bennett, 2010 .

Secondary acute myeloid leukemia after autologous bone marrow transplantation for malignant lymphomas.

C. Gisselbrecht, P. Morel, P. Brice, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

VIM3‐ARA C: An effective salvage regimen in refractory or recurrent aggressive non hodgkin's lymphoma. A report on 18 cases

P. Morel, P. Fenaux, F. Bauters, 2006, Hematological oncology.

Adult lymphoblastic lymphoma: a retrospective analysis of 92 patients under 61 years included in the LNH87/93 trials

R. Bouabdallah, S. Leprêtre, C. Sebban, 2003, Leukemia.

Peripheral T-cell Lymphoma with Eosinophilia Presenting as Monoarthritis: A Case Study

F. Sigaux, D. Bataille, P. Morel, 2002, Leukemia & lymphoma.

Autologous bone marrow transplantation as consolidation therapy may prolong remission in newly diagnosed high-risk follicular lymphoma: a pilot study of 34 cases.

P. Morel, L. Fouillard, L. Douay, 1995, Leukemia.

Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra-abdominal infections.

P. Morel, W. Zimmerli, S. Harbarth, 1999, International journal of antimicrobial agents.

Myelodysplasias and leukemias after autologous stem cell transplantation for lymphoid malignancies

C. Gisselbrecht, P. Morel, P. Rousselot, 2000, Bone Marrow Transplantation.

Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome

R. Siebert, P. Gaulard, R. De Wind, 2022, Haematologica.

Ascorbic acid (vitamin C) synergistically enhances the therapeutic effect of targeted therapy in chronic lymphocytic leukemia

P. Morel, L. Garçon, F. Nguyen‐Khac, 2020, Journal of Experimental & Clinical Cancer Research.

Treatment recommendations for patients with Waldenström's Macroglobulinemia (WM) and related disorders: consensus from the Seventh International Workshop on WM

R. Advani, E. Kimby, B. Barlogie, 2014 .

High incidence of lymphoid infiltration on labial salivary gland biopsy in non‐Hodgkin's lymphomas: clinical implications

P. Morel, F. Bauters, A. Janin, 1993, British journal of haematology.

International prognostic scoring system for Waldenstrom macroglobulinemia.

J. Crowley, B. Barlogie, M. Dimopoulos, 2009, Blood.

Translocation (3;13)(q27;q14): a nonrandom and probably secondary structural change in non-Hodgkin lymphomas.

P. Morel, P. Fenaux, F. Bauters, 1998, Cancer genetics and cytogenetics.

Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia.

E. Kimby, M. Dimopoulos, D. Maloney, 2006, Blood.

Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study

R. Houot, K. Hoang-Xuan, O. Chinot, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia

Marc C. Jacob, M. Boubaya, J. Rossi, 2020, Leukemia.

Four cases of follicular lymphoma with t(14;18)(q32;q21) and t(3;4)(q27;p13) with LAZ3 (BCL6) rearrangement.

P. Morel, J. Laï, S. Galiègue‐Zouitina, 1999, Cancer genetics and cytogenetics.

Does early disease progression predict survival after first line‐treatment of Waldenström macroglobulinemia?

A. Duhamel, P. Morel, L. Ysebaert, 2022, Hematological oncology.

Treatment of severe aplastic anemia with antilymphocyte globulin and androgens: A report on 33 patients

P. Morel, P. Fenaux, C. Gardin, 1991, Annals of Hematology.

Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials.

P. Gaulard, B. Coiffier, H. Tilly, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multivariate analysis of the survival of patients with aggressive lymphoma

B. Coiffier, H. Tilly, C. Gisselbrecht, 1998 .

p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies.

B. Quesnel, E. Wattel, C. Preudhomme, 1994, Blood.

All-transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases.

H. Dombret, H. Tilly, P. Morel, 1992, Blood.

International scoring system for evaluating prognosis in myelodysplastic syndromes.

T Hamblin, G. Mufti, P. Greenberg, 1997, Blood.

Accurate classification of plasma cell dyscrasias is achieved by combining artificial intelligence and flow cytometry

P. Morel, L. Garçon, T. Matthes, 2021, British journal of haematology.

Is ZAP-70 expression stable over time in B chronic lymphocytic leukaemia?

P. Morel, P. Duthilleul, S. Poulain, 2007, Leukemia & lymphoma.

Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).

P. Gaulard, F. Berger, B. Coiffier, 2003, Blood.

Cytogenetics and their prognostic value in childhood and adult acute lymphoblastic leukemia (ALL) excluding L3

O. Taboureau, P. Morel, P. Fenaux, 1989, Hematological oncology.

Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis.

J. Mary, P. Morel, F. Bauters, 1995, Blood.

Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort

P. Feugier, P. Morel, A. Delmer, 2021, Annals of Hematology.

Secondary acute lymphoblastic leukemia with t (4; 11): Report on two cases and review of the literature

P. Morel, P. Fenaux, F. Bauters, 1992, Annals of Hematology.

Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte).

C Sebban, B. Coiffier, H. Tilly, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Aggressive lymphomas with renal involvement: a study of 48 patients treated with the LNH-84 and LNH-87 regimens. Groupe d'Etude des Lymphomes de l'Adulte.

H. Tilly, A. Delannoy, C. Haioun, 1994, British Journal of Cancer.

Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte.

B. Coiffier, H. Tilly, C. Gisselbrecht, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

Pierre Morel, Raoul Herbrecht, Felix Reyes, 2002, The New England journal of medicine.

ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma.

T. Molina, B. Coiffier, H. Tilly, 2005, The New England journal of medicine.

Prognostic factors in Waldenstrom's macroglobulinemia: description of the complications during the evolution-preliminary results on 101 patients.

P. Morel, V. Leblond, B. Cazin, 2003, Seminars in oncology.

Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.

P. Gaulard, G. Salles, B. Coiffier, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognosis and treatment of lymphoblastic lymphoma in adults: a report on 80 patients.

C. Gisselbrecht, É. Lepage, P. Morel, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification during the follow-up of time-dependent prognostic factors for the competing risks of death and blast phase in primary myelofibrosis: a study of 172 patients.

A. Duhamel, P. Morel, B. Hivert, 2010, Blood.

Bone marrow versus peripheral blood progenitor cells CD34 selection in patients with non-Hodgkin's lymphomas: different levels of tumor cell reduction. Implications for autografting.

P. Morel, L. Fouillard, L. Douay, 1997, Blood.

Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: a report on 283 cases

R. Beuscart, C. Preudhomme, P. Morel, 1989, British journal of haematology.

Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia.

R. Advani, E. Kimby, M. Dimopoulos, 2016, Blood.

SDF1/CXCL12 (-801GA) polymorphism is a prognostic factor after treatment initiation in Waldenstrom macroglobulinemia.

P. Morel, X. Leleu, V. Coiteux, 2009, Leukemia research.

Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.

R. Advani, E. Kimby, B. Barlogie, 2014, Blood.

Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi‐institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO)

S. Leprêtre, P. Morel, A. Delmer, 2017, British journal of haematology.

A Recurrent Activating Missense Mutation in Waldenström Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances Proliferation.

O. Elemento, P. Vyas, F. Cosset, 2019, Cancer discovery.

International Prognostic Scoring System (IPSS) for Waldenström’s Macroglobulinemia (WM).

B. Barlogie, M. Dimopoulos, M. Dhodapkar, 2006 .

Lenalidomide is safe and active in Waldenström macroglobulinemia

G. Salles, P. Morel, X. Leleu, 2015, American journal of hematology.

Tandem autotransplant as first-line consolidative treatment in poor-risk aggressive lymphoma: a pilot study of 36 patients.

P. Gaulard, B. Quesnel, C. Gisselbrecht, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low–intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol

T. Molina, B. Coiffier, H. Tilly, 2010, Leukemia & lymphoma.

Prognostic factors in Waldenström's macroglobulinemia: a report of 167 cases.

A. Duhamel, P. Morel, P. Fenaux, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Congenital diserythropoietic anemia type I

P. Morel, P. Fenaux, T. Facon, 1990, Blut.

De novo myelodysplastic syndrome (MDS) with deletion of the long arm of chromosome 20: a subtype of MDS with distinct hematological and prognostic features?

E. Wattel, C. Preudhomme, P. Morel, 1993, Leukemia research.

Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patients

J. Tamburini, P. Morel, A. Delmer, 2005, Leukemia.

BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years.

M. Dimopoulos, P. Sonneveld, P. Morel, 2017, Blood.

Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy

M. Dimopoulos, P. Morel, E. Hatjiharissi, 2015, Haematologica.

Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma.

S. Chevret, P. Morel, V. Leblond, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic Validation of the International Classification of Immunoglobulin M Gammopathies: A Survival Advantage for Patients with Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance?

P. Gobbi, C. Broglia, L. Baldini, 2005, Clinical Cancer Research.

International prognostic scoring system for Waldenström s Macroglobulinemia Short title: Prognostic index for Waldenström Macroglobulinemia

J. Crowley, B. Barlogie, M. Dimopoulos, 2017 .

Combination Therapy with Rituximab and Fludarabine in Waldenstrom’s Macroglobulinemia.

E. Kimby, P. Morel, S. Treon, 2004 .

Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia

E. Kimby, C. Buske, J. Dreyhaupt, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Diagnostics in Waldenström’s macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia

M. Kersten, C. Buske, N. Puig, 2022, Leukemia.

Balancing risk versus benefit in the treatment of Waldenström's Macroglobulinemia patients with nucleoside analogue-based therapy.

J. Tamburini, P. Morel, S. Treon, 2009, Clinical lymphoma & myeloma.

Clinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenstrom macroglobulinemia.

S. Susen, A. Duhamel, P. Morel, 2012, Blood.

Can ISSWM be used for making treatment decisions?

P. Morel, G. Merlini, 2011, Clinical Lymphoma, Myeloma & Leukemia.

macroglobulinemia Long term outcomes to fludarabine and rituximab in Waldenstrom

P. Morel, S. Treon, A. Branagan, 2008 .

Hematopoietic Stem Cell Transplantation (HSCT) in Waldenström Macroglobulinemia (Wm), Update of the French Experience in 54 Cases.

M. Robin, P. Morel, G. Guillerm, 2007 .

Incidence of Disease Transformation and Development of MDS/AML in 165 Patients with Waldenström’s Macroglobulinemia (WM) Treated with Fludarabine (F)-Based Regimen in Three Studies (French Cooperative Group on CLL/WM)

J. Tamburini, P. Morel, V. Leblond, 2007 .

Report of the Third International Workshop on Waldenstrom's macroglobulinemia.

P. Morel, S. Treon, V. Leblond, 2005, Clinical lymphoma.

Activity of fludarabine in previously treated Waldenström's macroglobulinemia: a report of 71 cases. Groupe Coopératif Macroglobulinémie.

I. Yakoub-Agha, X. Mariette, P. Morel, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A prognostic index predicting survival in transformed Waldenström macroglobulinemia

M. Dimopoulos, S. Leprêtre, P. Morel, 2020, Haematologica.

Onsets of progression and second treatment determine survival of patients with symptomatic Waldenström macroglobulinemia.

A. Duhamel, P. Morel, L. Ysebaert, 2018, Blood advances.

CLINICAL TRIALS OBSERVATIONS BDR in newly diagnosed patients with WM: ﬁ nal analysis of a phase 2 study after a minimum follow-up of 6 years

M. Dimopoulos, P. Sonneveld, P. Morel, 2017 .

Comparison of prognostic scoring systems in primary myelofibrosis.

A. Duhamel, P. Morel, 2010, Blood.

Open Label Non-Randomized Phase II Study Exploring «Chemo-Free » Treatment Association with Idelalisib + Obinutuzumab in Patients with Relapsed/Refractory (R/R) Waldenstrom's Macroglobulinemia (MW), a Filo Trial: Results of the Intermediary Analysis of the Induction Phase

O. Casasnovas, S. Leprêtre, S. Chevret, 2019, Blood.

Bortezomib, Dexamethasone and Rituximab in Newly Diagnosed Patients with WaldenströM's Macroglobulinemia: Final Analysis of a Phase 2 Study after a Minimum Follow up of 6 Years

M. Dimopoulos, P. Sonneveld, P. Morel, 2016 .

Bortezomib and Waldenstrom's macroglobulinemia

P. Morel, A. Roccaro, I. Ghobrial, 2009 .

Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission. Groupe d'Etude les Lymphomes de l'Adulte (GELA).

C Sebban, G. Salles, R. Bouabdallah, 2000, Blood.

Azacitidine in untreated acute myeloid leukemia: A report on 149 patients

H. Dombret, A. Stamatoullas, B. Quesnel, 2014, American journal of hematology.

Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2.

P. Gaulard, G. Salles, M. Copin, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system.

A. Rossi, P. Gobbi, C. Broglia, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lenalidomide Is Safe and Active in Waldenstrom Macroglobulinemia (WM)

P. Morel, X. Leleu, V. Leblond, 2014 .

Bortezomib in Combination with Dexamethasone, Rituximab and Cyclophosphamide (B-DRC) As First – Line Treatment of Waldenstrom’s Macroglobulinemia: Results of a Prospectively Randomized Multicenter European Phase II Trial

E. Kimby, M. Dimopoulos, C. Buske, 2020 .

TCL1 expression patterns in Waldenström macroglobulinemia

P. Morel, X. Leleu, J. Bay, 2016, Modern Pathology.

Primary Therapy of Waldenström's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A Phase II Study of the European Myeloma Network

M. Dimopoulos, P. Sonneveld, P. Morel, 2009 .

Advanced Waldenström's macroglobulinemia: usefulness of Morel's scoring system in establishing prognosis.

R. Porcher, S. Chevret, E. Wattel, 2005, Haematologica.

Treatment of Acute Promyelocytic Leukemia: A Report of 70 Cases.

P. Morel, P. Fenaux, F. Bauters, 1991, Leukemia & lymphoma.

Short communication Frequency of structural abnormalities of the long arm of chromosome 12 in myelofibrosis with myeloid metaplasia

P. Morel, F. Bauters, J. Andrieux, 2002 .

A prospective phase II of daratumumab in previously treated systemic light chain amyloidosis (AL) patients.

S. Chevret, P. Morel, M. Macro, 2020, Blood.

Yttrium-90 Ibritumomab Tiuxetan (Zevalin) for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Appropriate for Autologous Stem Cell Transplantation: Results of an Open-Label Phase II Trial.

H. Stein, D. Huglo, R. Marcus, 2004 .

Autoimmune hemolytic anemias and IgG antierythrocyte autoantibodies in Waldenström's macroglobulinemia: association with FcγRIIa polymorphism

I. Dervite, P. Morel, X. Leleu, 2006, Leukemia.

[Waldenström's macroglobulinemia].

P. Morel, X. Leleu, B. Hivert, 2010, La Revue de medecine interne.

A Prospective Phase II of Daratumumab in Previously-Treated Systemic Light-Chain (AL) Amyloidosis

P. Morel, M. Macro, L. Frenzel, 2017 .

Immunomodulation with Azacytidine and Donor Lymphocyte Infusion Following Sequential Conditioning Allogenic Stem Cell Transplantation Improves Outcome of Unfavorable AML

P. Morel, L. Garçon, J. Marolleau, 2019, Blood.

Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management

E. Kimby, P. Morel, S. Treon, 2023, Seminars in Hematology.

Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.

J. Blay, A. Stamatoullas, B. Quesnel, 2000, Haematologica.

Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin ' s lymphomas

A. Stamatoullas, B. Quesnel, C. Haioun, 2000 .

EPIDEMIOLOGICAL LANDSCAPE OF YOUNG MULTIPLE MYELOMA PATIENTS DIAGNOSED EARLIER THAN 40 YEARS: THE FRENCH EXPERIENCE.

P. Morel, H. Avet-Loiseau, X. Leleu, 2021, Blood.

Primary Sjögren ’ s syndrome and aplastic anaemia

F. Sigaux, P. Morel, F. Bauters, 1998 .

[Autologous bone marrow graft in the initial treatment of follicular lymphomas in young high risk subjects. A new therapeutic approach].

P. Morel, P. Fenaux, L. Fouillard, 1991, Presse medicale.

Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management

E. Kimby, P. Morel, S. Treon, 2023, Seminars in Hematology.

JAK2 V617F mutation is absent in chronic lymphocytic leukemia

P. Morel, M. Simon, P. Duthilleul, 2006, Leukemia & lymphoma.

MONOMORPHIC EPITHELIOTROPIC INTESTINAL T‐CELL LYMPHOMA (MEITL): CLINICO‐PATHOLOGICAL ANALYSIS OF A MULTICENTER EUROPEAN COHORT

P. Gaulard, L. Xerri, M. Copin, 2021, Hematological Oncology.

Retrospective Analysis of 56 Cases of Transformed Waldenström Macroglobulinemia. a Study on Behalf of the French Innovative Leukemia Organization (FILO)

S. Leprêtre, P. Morel, A. Delmer, 2016 .

Evaluation and Management of Disease Transformation in Waldenström Macroglobulinemia.

P. Morel, A. Delmer, E. Durot, 2023, Hematology/oncology clinics of North America.

Response to vaccination against SARS‐CoV‐2 in 168 patients with Waldenström macroglobulinaemia: A French Innovative Leukaemia Organization study

P. Morel, K. Laribi, V. Leblond, 2022, British journal of haematology.

Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi‐institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO)

S. Leprêtre, P. Morel, A. Delmer, 2017 .

Melanoma progression and serum l-dopa/l-tyrosine ratio: a comparison with S100B

P. Morel, P. Morel, G. Ghanem, 2002, Melanoma research.

Bendamustine rituximab (BR) versus ibrutinib (Ibr) as primary therapy for Waldenström macroglobulinemia (WM): An international collaborative study.

M. Dimopoulos, R. Kyle, Shaji K. Kumar, 2022, Journal of Clinical Oncology.

Genome Wide SNP Analysis Reveals Frequent Cryptic Clonal Chromosomal Aberrations Including Uniparental Disomy (UPD) in Waldenstrom's Macroglobulinemia.

C. Preudhomme, P. Morel, X. Leleu, 2009 .

patients with the description of a new scoring system and its validation on 253 other patients.

B. Grosbois, E. Wattel, I. Dervite, 2000, Blood.

Polymorphism of the proto-oncogene ETS-1 in hematological malignancies.

B. Debuire, P. Morel, P. Fenaux, 1990, Leukemia.

[Familial thymoma and translocation t (14;20) (q24;p13)].

F. Vasseur, P. Morel, F. Bauters, 1994, Annales de genetique.

Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management

E. Kimby, P. Morel, S. Treon, 2023, Seminars in Hematology.

Azacitidine in untreated acute myeloid leukemia: A report on 149 patients

H. Dombret, A. Stamatoullas, B. Quesnel, 2014, American journal of hematology.

Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia.

E. Kimby, M. Dimopoulos, R. Kyle, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years.

M. Dimopoulos, P. Sonneveld, P. Morel, 2017, Blood.

Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia.

E. Kimby, P. Morel, S. Treon, 2008, Blood.

Lenalidomide is safe and active in Waldenström macroglobulinemia

G. Salles, P. Morel, X. Leleu, 2015, American journal of hematology.

Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia

B. Quesnel, E. Bertrand, C. Preudhomme, 2013, American journal of hematology.

High frequency of central nervous system involvement in transformed Waldenström macroglobulinemia

M. Dimopoulos, S. Leprêtre, P. Morel, 2022, Blood advances.